Reinhart Partners LLC. Reduces Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Reinhart Partners LLC. reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 15.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,243,591 shares of the medical equipment provider's stock after selling 225,066 shares during the quarter. Lantheus accounts for about 5.2% of Reinhart Partners LLC.'s holdings, making the stock its biggest holding. Reinhart Partners LLC. owned approximately 1.79% of Lantheus worth $136,484,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. UMB Bank n.a. raised its position in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. CWM LLC raised its position in Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock valued at $82,000 after purchasing an additional 290 shares during the last quarter. Tealwood Asset Management Inc. bought a new position in Lantheus in the third quarter valued at about $1,182,000. City Center Advisors LLC bought a new position in Lantheus in the third quarter valued at about $419,000. Finally, GAMMA Investing LLC raised its position in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after purchasing an additional 146 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the sale, the chief accounting officer now owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the completion of the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,322 shares of company stock valued at $2,731,150. Company insiders own 1.50% of the company's stock.

Lantheus Trading Up 3.7 %

NASDAQ LNTH traded up $4.02 during trading hours on Friday, hitting $112.19. 486,087 shares of the company's stock were exchanged, compared to its average volume of 983,696. The stock has a 50-day simple moving average of $104.20 and a 200 day simple moving average of $89.30. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of 17.13 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same period in the prior year, the business earned $1.40 EPS. The company's revenue for the quarter was up 22.5% on a year-over-year basis. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Truist Financial dropped their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. JMP Securities decreased their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Leerink Partners increased their price target on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target for the company. Finally, B. Riley increased their price target on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.